TechBio innovator: CardiaTec case study


CardiaTec, a University of Cambridge spinout, uses AI to analyse multi-omics data to discover new drug targets for cardiovascular diseases. The latest BIA’s TechBio 2023, the UK driving AI revolution report case study explores the opportunities, challenges and benefits in the CardiaTec new technology. 

What does the company do?

CardiaTec is the first AI-enabled drug target discovery company specialised in cardiovascular disease, the leading cause of death globally. Its human-centric, multi-omics approach allows for the identification of novel and better biologically defined drug targets with an increased probability of clinical success. 

How does the technology work?

CardiaTec is building the first and largest proprietary multi-omics dataset of human cardiac tissue. This platform integrates various biological data layers, including genomics, transcriptomics, epigenomics, and proteomics, to provide a comprehensive understanding of disease biology. By employing advanced AI algorithms, CardiaTec identifies and prioritises dysregulated drug targets and disease-related pathways. This approach enables the discovery of drug targets with well-defined mechanisms of action that are causal of disease thereby increasing the likelihood of successful clinical translation.

How will it be used?

CardiaTec’s initial focus is on coronary artery disease. The platform has incorporated multi-omics data from coronary tissues. Unlike traditional targeted omics data analysis and hypothesis-driven drug target discovery, CardiaTec’s model employs a fully unbiased multi-omics approach. This enables the models to suggest new pathways and proteins without being influenced by current knowledge or scientific expectations. This approach fosters the discovery of entirely novel pathways that might not have been previously considered in the development of therapeutics for coronary artery disease.


What are the opportunities and challenges?

Challenges in cardiovascular disease space: 

  • Cardiovascular disease is the leading cause of death globally, yet therapeutic innovation has been stagnant. The drug development pipeline for cardiovascular disease has experienced minimal growth in the last 10 years compared to other therapeutic areas despite the high mortality rate
  • The complexity and multifactorial nature of cardiovascular disease pose significant challenges in understanding its underlying pathophysiology. Current investigative techniques, such as single omics analysis, provide a limited understanding of disease mechanisms, impeding the identification of effective drug targets. Consequently, the clinical translation of associated drugs has been suboptimal, leaving a substantial unmet need for more effective treatments.


  • Cardiovascular disease represents a significant global health concern, offering a substantial market for innovative therapies
  • There’s potential for substantial advancements in drug development for cardiovascular disease, considering the relatively stagnant progress in recent years
  •  The emergence of more comprehensive technologies, including multi-omics, allows for the complexity of cardiovascular biology to be better captured.

What are the future trends?

CardiaTec plans to expand its multi-omics data generation and drug target discovery to encompass additional cardiovascular indications in the future.



More news and updates

Deep Biotech companies using engineering biology for good: Epoch Biodesign case study

Featured in BIA's Deep Biotech report, Epoch Biodesign aims to revolutionize plastic waste management by creating tailor-made enzymes that efficiently depolymerize a wide range of plastics into recyclable materials, offering a circular solution to tackle plastic pollution and promote sustainability.

Women in Biotech Mentoring Programme: Helen and Kathryn's experience

In this interview, consultant and best-selling author Kathryn Simpson, together with patent attorney Helen Bartlett, dive into their reasons for joining the BIA's Women in Biotech mentoring programme, and how this experience has impacted their professional and personal lives.

Deep Biotech companies using engineering biology for good: Solena Materials case study

Solena Materials is a pioneering biotech company spun out from Imperial College London, specialising in the development of computationally designed synthetic protein materials, originally featured in BIA's Deep Biotech report on disruptive innovation for global sustainability.

CEO Update - 13 May 2024

It was wonderful to celebrate with RNID, our charity partner of the year, the news that pioneering gene therapy has restored a UK girl's hearing. Read on for updates on MHRA AI-Airlock, AMR action plan and more...

Accelerating biotech innovations and predicting genetic codes: Spotlight on Ingenza

Meet Ian Fotheringham, the Managing Director of Ingenza, a global CRDMO that aims to accelerate clients' journeys from discovery to clinical trials while minimising costs and risks. Their innovative codABLE® algorithm brings predictability to DNA sequence configuration, revolutionizing recombinant production of pharmaceutical and industrial molecules. Join us as we explore Ian's insights and Ingenza's ambitious goals for the future.

Deep Biotech companies using engineering biology for good: Moa Technology case study

A spin-out from Oxford University, Moa Technology is developing next-generation herbicides to tackle a growing crisis in agriculture. Read more in BIA's Deep Biotech report on disruptive innovation for global sustainability.

A critical time for AI, dementia and better brain health

Ahead of BioBeat24, Iraida Soria-Espinosa, Senior Innovation & Business Manager at UK DRI, and Miranda Weston-Smith, Founder of BioBeat, caught up with keynote speaker Zoe Kourtzi, Professor of Computational Cognitive Neuroscience at the University of Cambridge.

CEO Update - 7 May 2024

It’s SynBioBeta week and the UK engineering biology community is out in force in San Jose, California. The BIA is leading a coalition of UK stakeholders to showcase the dynamism and innovation of the UK's companies. Read on for updates on local election results, Innovation Map and Deaf Awareness Week...

Paul Freemont's speech on engineering biology at 10 Downing Street reception

Professor Paul Freemont, Faculty of Medicine, Department of Infectious Disease at Imperial College shares insights from his speech at the 10 Downing Street reception. Discover the dynamic landscape of UK engineering biology, where innovation meets sustainability, and explore the vibrant ecosystem of pioneering companies poised to revolutionize industries worldwide.

Deep Biotech companies using engineering biology for good: Evonetix case study

Evonetix is developing a new tool that lets researchers build the building blocks of life – genes – faster and easier than ever before. This could lead to breakthroughs in medicine and agriculture. Read more in BIA's Deep Biotech report on disruptive innovation for global sustainability.


More within